Globus Medical Inc. entered into a definitive agreement to buy Nuvasive Inc. in an all-stock transaction that will combine two leaders in the musculoskeletal industry into one of the largest companies in the spinal surgery market. While there are many companies in the spine market, the acquisition may still set off an alarm among regulators concerned about consolidation in the field. Both boards unanimously approved the deal.

Tonix Pharmaceuticals Holding Corp. has announced it plans to develop the TNX-3900 series of oral antivirals as monotherapy or in combination with other antivirals, following an agreement whereby it has acquired all of the assets of Healion Bio Inc., including its entire portfolio of next-generation antiviral technology assets.

Companion Spine SAS has acquired Backbone SAS, a company that develops implantable functional motion restoration devices for treating spinal disorders. The inclusion of Backbone's flagship medical device, Lisa – a lumbar implant for stiffness augmentation – completes the Companion Spine portfolio.

Newly spun out GE Healthcare Technologies Inc. presented preliminary results for the fourth quarter and full year 2022 at the 41st annual J.P. Morgan Healthcare Conference on Tuesday. The update followed the announcement of plans to purchase Imactis SAS, which developed CT-Navigation, a stereotactic needle guidance system. Terms of the Imactis deal were not disclosed.

Zimmer Biomet Holdings Inc. (ZBH) agreed to acquire Embody Inc. for $155 million at closing with an additional $120 million in contingent milestone payments over the next three years. The deal includes Embody’s entire portfolio of collagen-based regenerative solutions for soft tissue injuries. The transaction is expected to close in February.

Tandem Diabetes Care Inc. entered a definitive agreement to acquire AMF Medical SA for CHF 62.4 million (US$67.1 million) in cash at closing plus future payments of as much as CHF 129.6 million (US$139.43 million) contingent on meeting certain milestones. Tandem also invested CHF 8 million (US$8.6 million) in AMF in the third quarter of 2022. The transaction is expected to close in January 2023.

Full-Life Technologies Ltd. reported that it will acquire Focus-X Therapeutics Inc. to expand its radiopharmaceutical oncology therapy pipeline in a deal worth up to $245 million.

In a move that put Ekso Bionics Holdings Inc. on a path to walk over other firms developing exoskeletons, the company acquired the Human Motion and Control (HMC) business unit from Parker Hannifin Corp. The deal expands Ekso’s lower-limb exoskeleton line to include the Indego Personal and Indego Therapy devices, which like its own exoskeleton platform, help patients recovering from stroke or spinal cord injuries walk again. The transaction also includes the development of related robotic-assisted orthotic and prosthetic devices.

Full-Life Technologies Ltd. reported that it will acquire Focus-X Therapeutics Inc. to expand its radiopharmaceutical oncology therapy pipeline in a deal worth up to $245 million.